Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sandesh Mahatme Insider Profile
4 Followers
Sandesh Mahatme, EVP, CFO & CBO at Sarepta Therapeutics, holds 32.27K shares in Sarepta Therapeutics (Ticker: SRPT), holds ― shares in Spyre Therapeutics (Ticker: SYRE), holds 4.50K shares in Flexion Therapeutics (Ticker: FLXN). Most recently, Sandesh Mahatme Bought ― shares of Sarepta Therapeutics on Jul 09, 2020 for an estimated value of 74.94K.
Sandesh Mahatme Sarepta Therapeutics (SRPT)EVP, CFO & CBO
Sarepta Therapeutics (SRPT)
EVP, CFO & CBO
Ranked #46,679 out of 98,501 Corporate Insiders
Profitable Transactions
2 out of 3 Profitable Transactions
Average Return
+1.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Sandesh Mahatme holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Nov 10, 2016 - Nov 10, 2017
Return:+32.00%
The most profitable trade made by Sandesh Mahatme
Sandesh Mahatme's Trading History
Sarepta Therapeutics
Jul 09, 2020
EVP, CFO & CBO
Informative Buy
74.94K
$3.76M
Spyre Therapeutics
―
Director
―
―
Flexion Therapeutics
Jun 12, 2020
―
Uninformative Buy
―
$41.04K
List of latest transactions for each holding click on a transaction to see Sandesh Mahatme's performance on stock
You May Also Like
Sandesh Mahatme insider profile FAQ
What is the percentage of profitable transactions made by Sandesh Mahatme?
The percentage of profitable transactions made by Sandesh Mahatme is 67%.
What is the average return per transaction made by Sandesh Mahatme?
The average return per transaction made by Sandesh Mahatme is 1.20%.
What stocks does Sandesh Mahatme hold?
Sandesh Mahatme holds: SRPT, SYRE, FLXN stocks.
What was Sandesh Mahatme’s latest transaction?
Sandesh Mahatme latest transaction was an Informative Buy of $74.94K.
What was Sandesh Mahatme's most profitable transaction?
Sandesh Mahatme’s most profitable transaction was an Informative Buy of SRPT stock on November 10, 2016. The return on the trade was 32.00%.
What is Sandesh Mahatme's role in Sarepta Therapeutics?
Sandesh Mahatme's role in Sarepta Therapeutics is EVP, CFO & CBO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.